Krishna Institute of Medical Sciences Limited (KIMS)
₹685.60 -0.44% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Krishna Institute's revenue was ₹1,180 Cr (+35.3% year on year, +9.7% on the previous quarter), and net profit ₹37.4 Cr (-56.0% year on year); the operating margin was 18.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1,180 | +35.3% | +9.7% |
| Operating profit | ₹223 | +15.8% | +8.4% |
| Net profit | ₹37.4 | -56.0% | +13.3% |
| EPS (₹) | 1.04 | -46.9% | -1.9% |
| Operating margin | 18.9% | — | — |
KIMS delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 46.92% of the KIMS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 55.08%. That is close to its usual level. Volume was 0.3 times its average, well below normal.
Delivery in the last 5 sessions: 56.0% · 53.0% · 40.9% · 44.3% · 46.9%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Krishna Institute of Medical Sciences Limited (KIMS) has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended 30th September 2026. The certificate was issued by the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited). The filing confirms that all share certificates received for dematerialisation during the quarter were duly processed, accepted or rejected, and cancelled within statutory timelines. This is a standard administrative compliance filing with no impact on business operations or financials.
- Regulation 74(5) compliance certificate submitted for the quarter ended 30th September 2026
- Confirmation issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited on 03-10-2026
- Filing submitted to BSE and NSE on 10th October 2026
- Confirmation that dematerialised security certificates were mutilated and cancelled within prescribed timelines
Krishna Institute of Medical Sciences (KIMS) has issued a corrigendum regarding its October 06, 2026 acquisition-related filing, correcting significant typographical errors in the financial metrics of two target entities. For Insignia Healthcare Private Limited, net worth was revised downwards by 90% from ₹243.3 Crore to ₹24.3 Crore, and turnover was corrected from ₹104.5 Crore to ₹9.68 Crore. Additionally, Sarvottam Health Care Private Limited's PAT was revised down from ₹70.55 Crore to ₹7.06 Crore. All other terms and conditions from the original intimation remain unchanged.
- Insignia Healthcare net worth corrected to ₹24.3 Crore from ₹243.3 Crore (a 90% reduction)
- Insignia Healthcare turnover corrected to ₹9.68 Crore from ₹104.5 Crore (a 91% reduction)
- Sarvottam Health Care PAT corrected to ₹7.06 Crore from ₹70.55 Crore (a 90% reduction)
- Correction follows the initial Regulation 30 acquisition disclosures dated October 06, 2026
KIMS has approved the acquisition of up to a 51% equity stake in Insignia Healthcare Private Limited (KIMS-SIKHARA), an O&M entity operating a 150-bed hospital in Guntur, Andhra Pradesh (expandable to 200 beds). The acquisition will be conducted via cash consideration at Rs 30.35 per share based on an independent valuation, structured as a creeping acquisition over 12 to 24 months. Insignia Healthcare posted a turnover of Rs 104.5 crore in FY25 (reported elsewhere in the filing as Rs 9.68 crore turnover with a loss of Rs 13.28 crore for FY24-25) and has a net worth of Rs 243.3 crore. This transaction solidifies KIMS's footprint in Andhra Pradesh by moving from an O&M manager to a majority equity owner.
- Board approved acquisition of up to 51.00% equity stake in Insignia Healthcare Private Limited on a fully diluted basis.
- Target operates a 150-bed hospital in Guntur with potential expansion to 200 beds.
- Shares to be acquired in cash at Rs 30.35 per equity share based on BDO Valuation Advisory LLP report.
- Indicative completion timeline is 12 to 24 months via creeping acquisition.
- Target reported net worth of Rs 243.3 crore and FY25 turnover of Rs 104.5 crore (with FY24-25 PAT at -Rs 13.28 crore).
KIMS has approved the acquisition of up to a 51% equity stake in Insignia Healthcare Private Limited (KIMS-SIKHARA), an O&M entity operating a 150-bed hospital in Guntur, Andhra Pradesh (expandable to 200 beds). The acquisition will be conducted via cash consideration at Rs 30.35 per share based on an independent valuation, structured as a creeping acquisition over 12 to 24 months. Insignia Healthcare posted a turnover of Rs 104.5 crore in FY25 (reported elsewhere in the filing as Rs 9.68 crore turnover with a loss of Rs 13.28 crore for FY24-25) and has a net worth of Rs 243.3 crore. This transaction solidifies KIMS's footprint in Andhra Pradesh by moving from an O&M manager to a majority equity owner.
- Board approved acquisition of up to 51.00% equity stake in Insignia Healthcare Private Limited on a fully diluted basis.
- Target operates a 150-bed hospital in Guntur with potential expansion to 200 beds.
- Shares to be acquired in cash at Rs 30.35 per equity share based on BDO Valuation Advisory LLP report.
- Indicative completion timeline is 12 to 24 months via creeping acquisition.
- Target reported net worth of Rs 243.3 crore and FY25 turnover of Rs 104.5 crore (with FY24-25 PAT at -Rs 13.28 crore).
KIMS has approved the acquisition of up to a 51% equity stake in Insignia Healthcare Private Limited (KIMS-SIKHARA), an O&M entity operating a 150-bed hospital in Guntur, Andhra Pradesh (expandable to 200 beds). The acquisition will be conducted via cash consideration at Rs 30.35 per share based on an independent valuation, structured as a creeping acquisition over 12 to 24 months. Insignia Healthcare posted a turnover of Rs 104.5 crore in FY25 (reported elsewhere in the filing as Rs 9.68 crore turnover with a loss of Rs 13.28 crore for FY24-25) and has a net worth of Rs 243.3 crore. This transaction solidifies KIMS's footprint in Andhra Pradesh by moving from an O&M manager to a majority equity owner.
- Board approved acquisition of up to 51.00% equity stake in Insignia Healthcare Private Limited on a fully diluted basis.
- Target operates a 150-bed hospital in Guntur with potential expansion to 200 beds.
- Shares to be acquired in cash at Rs 30.35 per equity share based on BDO Valuation Advisory LLP report.
- Indicative completion timeline is 12 to 24 months via creeping acquisition.
- Target reported net worth of Rs 243.3 crore and FY25 turnover of Rs 104.5 crore (with FY24-25 PAT at -Rs 13.28 crore).
KIMS has approved the acquisition of up to a 51% equity stake in Insignia Healthcare Private Limited (KIMS-SIKHARA), an O&M entity operating a 150-bed hospital in Guntur, Andhra Pradesh (expandable to 200 beds). The acquisition will be conducted via cash consideration at Rs 30.35 per share based on an independent valuation, structured as a creeping acquisition over 12 to 24 months. Insignia Healthcare posted a turnover of Rs 104.5 crore in FY25 (reported elsewhere in the filing as Rs 9.68 crore turnover with a loss of Rs 13.28 crore for FY24-25) and has a net worth of Rs 243.3 crore. This transaction solidifies KIMS's footprint in Andhra Pradesh by moving from an O&M manager to a majority equity owner.
- Board approved acquisition of up to 51.00% equity stake in Insignia Healthcare Private Limited on a fully diluted basis.
- Target operates a 150-bed hospital in Guntur with potential expansion to 200 beds.
- Shares to be acquired in cash at Rs 30.35 per equity share based on BDO Valuation Advisory LLP report.
- Indicative completion timeline is 12 to 24 months via creeping acquisition.
- Target reported net worth of Rs 243.3 crore and FY25 turnover of Rs 104.5 crore (with FY24-25 PAT at -Rs 13.28 crore).
Krishna Institute of Medical Sciences Limited (KIMS) has announced its participation in the Anand Rathi Annual Flagship Conference G-200 Summit 2026. The group meeting is scheduled to be held in Mumbai on September 22, 2026. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the interactions.
- Meeting scheduled for September 22, 2026
- Event: Anand Rathi Annual Flagship Conference G-200 Summit 2026
- Format: Group Meeting in Mumbai, India
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be shared
Krishna Institute of Medical Sciences Limited (KIMS) has scheduled participation in the J.P. Morgan India Conference on September 21, 2026, in Mumbai. The interaction will be a group meeting with analysts and institutional investors. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the interactions. This is a routine institutional outreach intimation filed under Regulation 30 of SEBI LODR.
- Meeting scheduled for September 21, 2026
- Event: J.P. Morgan India Conference in Mumbai, India
- Meeting format: Group Meeting
- No Unpublished Price Sensitive Information (UPSI) to be shared
Krishna Institute of Medical Sciences (KIMS) has entered into an Operations and Management (O&M) Agreement with Sarvottam Health Care Private Limited (SHPL) to manage Trust Multi Speciality Hospital in Kakinada, Andhra Pradesh. The agreement runs for an initial term of 5 years, extendable by another 5 years on an exclusive basis. Under the deal, KIMS will receive an asset-light revenue fee of 9% of the hospital's Net Revenue. The facility currently operates with an installed capacity of 183 beds across a G+7 structure spanning 9,847.23 sq meters.
- Exclusive O&M agreement for an initial term of 5 years, extendable by a further 5 years
- KIMS entitled to receive a management fee of 9% of the hospital's Net Revenue
- Hospital has an installed capacity of 183 beds in Kakinada, Andhra Pradesh
- Infrastructure includes a cellar + ground + 7 floors structure with 9,847.23 sq meters built-up area
Krishna Institute of Medical Sciences Limited (KIMS) has scheduled an in-person Institutional Investor Meeting on Thursday, September 10, 2026, starting at 2:30 PM IST. The meeting is hosted by Emkay Global Group and will take place at KIMS Mahadevpura. The company confirmed that discussions will strictly be based on publicly available information and no unpublished price-sensitive information (UPSI) will be shared.
- Institutional investor meeting scheduled for Thursday, September 10, 2026
- Meeting time set from 2:30 p.m. (IST)
- Hosted by Emkay Global Group in person at KIMS Mahadevpura
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be shared
Krishna Institute of Medical Sciences Limited (KIMS) has declared the voting results for its 24th Annual General Meeting held on August 27, 2026. All five ordinary and special resolutions were approved by shareholders, with total voter turnout representing ~84.9% of outstanding shares. Special resolutions approving loans/guarantees under Section 185 and overall investment/loan limits under Section 186 passed with ~78.4% and ~78.5% approval respectively, despite ~41% institutional opposition on both items. The adoption of FY26 financial statements was passed unanimously.
- Overall voter turnout stood at 84.89% across 35.66 crore votes polled out of 42.00 crore shares.
- Special resolutions under Section 185 and Section 186 passed with 78.38% and 78.50% favourable votes respectively.
- Substantial institutional dissent recorded for Section 185 (41.32% against) and Section 186 (41.09% against) resolutions.
- Director re-appointment of Ms. Dandamudi Anitha passed with 74.46% overall approval, seeing 49.49% institutional votes against.
Krishna Institute of Medical Sciences Limited (KIMS) conducted its 24th Annual General Meeting on August 27, 2026, with 71 members attending via video conference. Key resolutions tabled included the adoption of FY26 financial statements, the re-appointment of retiring director Ms. Dandamudi Anitha, and statutory ratification of cost auditor remuneration. Additionally, shareholders voted on special resolutions approving loan and guarantee limits under Sections 185 and 186 of the Companies Act, 2013. Voting results and the scrutinizer's report will be disclosed separately.
- 24th AGM conducted on August 27, 2026, between 4:00 PM and 6:00 PM IST with 71 members present
- Tabled adoption of FY26 audited financial statements (consolidated and standalone)
- Sought approval for limits under Section 185 and Section 186 for loans, guarantees, securities, and investments
- Final voting results to be submitted post scrutinizer report compilation
Krishna Institute of Medical Sciences (KIMS) has issued a clarification to the stock exchanges refuting media reports published on Dealstreetasia.com regarding an alleged $52 million stake acquisition in Renova Hospitals. The company stated that the article is completely false, baseless, and factually incorrect. KIMS confirmed that it has neither entered into any agreement or MoU nor engaged in any acquisition discussions with Renova Hospitals. The rumored $52 million deal (~₹430 crore) would have represented approximately 11.7% of KIMS's TTM revenue of ₹3,682 crore.
- KIMS refuted media reports dated 25th August 2026 alleging an acquisition of Renova Hospitals
- Reported deal value of $52 Million (~₹430 crore) declared completely baseless and incorrect
- Confirmed no discussions, MoUs, or binding/non-binding agreements have taken place
- Company reiterated adherence to Regulation 30 disclosures for any genuine corporate developments
Krishna Institute of Medical Sciences (KIMS) has entered into an exclusive Operations and Management (O&M) Agreement and Call Option Agreement with Aurevia Hospitals to operate Arete Hospitals, a 250-bed multispecialty facility in Gachibowli, Hyderabad. The agreement spans an initial term of 5 years, extendable by another 5 years. KIMS will receive a management fee of 9% of the hospital's Net Revenue. Additionally, the call option provides KIMS the right, but not the obligation, to acquire the hospital business in the future.
- Exclusive O&M agreement for a 250-bed multispecialty hospital in Gachibowli, Hyderabad
- Initial agreement term of 5 years with a 5-year extension option
- Management fee set at 9% of total Net Revenue (gross revenue minus discounts/concessions)
- Call Option Agreement grants KIMS the option to acquire the business at definitive valuation terms
Krishna Institute of Medical Sciences Limited (KIMS) has allotted 77,02,182 fully convertible warrants on a preferential basis to promoter and promoter group entities. The company received Rs 149.99 Cr upfront, representing 25% of the total issue price of approximately Rs 600 Cr. Upon full conversion within 18 months, the aggregate promoter holding will increase from 32.50% to 33.71%.
- Allotted 77,02,182 convertible warrants on preferential basis to Promoters Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP
- Received Rs 1,499,999,944.50 (Rs 149.99 Cr) as 25% upfront warrant subscription money
- Implies an effective warrant issue price of ~Rs 779 per share and a total equity fundraise of ~Rs 600 Cr
- Promoter and Promoter Group shareholding to rise from 32.50% to 33.71% upon full conversion
- Warrants are exercisable into equity shares within 18 months from the allotment date (19 August 2026)
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 21% YoY to INR 3,039 Cr in FY25 from INR 2,503 Cr in FY24. Growth was driven by a 22% CAGR between FY20-24, supported by bed additions and improved ARPOBD. The flagship Secunderabad hospital's revenue contribution has been successfully diluted from 60% in FY18 to <35% in FY25.
Geographic Revenue Split
Telangana and Andhra Pradesh remain the core markets with 15 hospitals. Expansion is underway in Maharashtra (Nashik, Mumbai, Nagpur), Karnataka (Bengaluru), and Kerala. The Secunderabad flagship now accounts for <35% of revenue, down from 60% in FY18, indicating improved geographic diversification.
Profitability Margins
PAT margin stood at 13.6% in FY25 (INR 415 Cr) compared to 13.4% in FY24 (INR 336 Cr). Operating margins improved by 30 bps to 26.3% in FY25 from 26% in FY24. RoCE moderated to 16.5% in FY25 from 18.1% in FY24 due to aggressive front-ended capex but is expected to stabilize between 12-15%.
EBITDA Margin
Operating profitability is maintained at 25-26% as of FY25. While new greenfield hospitals in Nashik and Bengaluru may cause a temporary drag, the company expects to sustain margins above 25% due to high operational efficiency and quick turnaround of acquired assets.
Capital Expenditure
KIMS incurred INR 1,792 Cr capex in FY25 for greenfield projects in Thane and Bengaluru. Planned capex of INR 2,200-2,500 Cr is scheduled between FY26 and FY28 to add 2,000 beds and establish oncology departments.
Credit Rating & Borrowing
Long-term rating upgraded to CRISIL AA/Stable from CRISIL AA-/Positive in April 2024; short-term rating reaffirmed at CRISIL A1+. Interest coverage ratio moderated to 8.24x in FY25 from 11.99x in FY24 due to increased debt servicing requirements.
Operational Drivers
Raw Materials
Medical consumables, surgical implants, and pharmaceuticals represent the primary operational costs, though specific percentage of total cost is not disclosed in available documents.
Capacity Expansion
Current capacity is 3,975 beds as of Dec 2023. KIMS added 1,000 beds in FY25 (including 325 beds in Nashik). Planned expansion includes 1,100 beds in FY26 and another 1,000 beds across FY27-28, with a long-term target of 3,000 beds in Kerala via the O&M model.
Raw Material Costs
Not disclosed as a specific percentage of revenue; however, operating efficiencies are driven by a 3.66-day Average Length of Stay (ALOS) in FY25, down from 4.11 days in FY24, which optimizes consumable usage per patient.
Manufacturing Efficiency
Operational efficiency is reflected in high ARPOBD and 'good' occupancy levels. The group achieved a 30 bps improvement in operating margin to 26.3% in FY25 through better performance at Begumpet and Nagpur facilities.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be achieved through a mix of greenfield expansions (Bengaluru hospitals starting in 3-4 months), brownfield additions (2,000 beds by FY28), and an asset-light O&M model in Kerala targeting 3,000 beds. The strategy focuses on reducing flagship dependence and expanding into high-ARPOB markets like Mumbai and Bengaluru.
Products & Services
Tertiary and quaternary healthcare services including cardiology, oncology, neurology, and multi-specialty surgical procedures.
Brand Portfolio
KIMS Hospitals, Sunshine Hospitals (Sarvejana Healthcare).
New Products/Services
Expansion into specialized Oncology departments across the hospital network is a key focus for the FY26-28 capex cycle.
Market Expansion
Entry into Bengaluru (2 hospitals in 3-4 months), Thane, and Kerala (O&M model) to diversify beyond the core Telangana/AP cluster.
Market Share & Ranking
One of the leading tertiary care players in Andhra Pradesh and Telangana; Secunderabad facility is one of the largest single-location hospitals in India with ~1,000 beds.
Strategic Alliances
General Atlantic holds a 42.6% minority stake. KIMS also uses an O&M (Operations and Management) model for expansion in Kerala to receive management fees without heavy capital outlay.
External Factors
Industry Trends
The hospital industry is seeing a shift toward regional consolidation and 'hub-and-spoke' models. KIMS is positioning itself by expanding from its Hyderabad hub into adjacent states while maintaining a high-margin tertiary care focus.
Competitive Landscape
Competes with other major multi-specialty chains in South and West India; competitive edge maintained through lower capital cost per bed and efficient turnaround of acquired assets.
Competitive Moat
The primary moat is the 'Doctor-Partnership' model which creates high switching costs for top surgeons and ensures stable clinical outcomes. This is sustainable as it aligns physician incentives with hospital profitability.
Macro Economic Sensitivity
Sensitive to healthcare spending trends and government reimbursement rates for institutional payers (CGHS/ECHS).
Consumer Behavior
Increasing preference for insurance-backed private healthcare over government facilities, with insurance and institutional payers now making up 70% of the KIMS payer mix.
Geopolitical Risks
Minimal direct impact, though global supply chains for high-end medical machinery (MRI, CT scanners) could be affected by trade barriers.
Regulatory & Governance
Industry Regulations
Subject to National Pharmaceutical Pricing Authority (NPPA) caps on medical devices/implants and state-level clinical establishment acts. Compliance with empanelment criteria for government schemes (CGHS/ECHS) is critical for volume.
Risk Analysis
Key Uncertainties
The primary risk is the successful ramp-up of 2,000 new beds. Failure to achieve optimal occupancy could lead to Debt/EBITDA exceeding the projected 3.5x in FY26, potentially impacting credit metrics.
Geographic Concentration Risk
While reducing, the company still has significant concentration in Telangana and Andhra Pradesh, making it vulnerable to regional regulatory changes or local competition.
Third Party Dependencies
High dependency on key doctors; however, this is mitigated by the equity-sharing model.
Technology Obsolescence Risk
Medical technology requires constant reinvestment; KIMS is addressing this through its INR 2,200-2,500 Cr capex plan which includes new oncology equipment.
Credit & Counterparty Risk
40% of revenue comes from government/institutional payers (CGHS/ECHS), which typically have longer receivable cycles compared to cash/insurance patients.
